Gan & Lee Pharmaceuticals.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS10
PHASE 3 / 2-38
RECRUITING5
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO0%
Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Gan & Lee Pharmaceuticals. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GZR4 NCT06767748 |
P3 | Active, not recruiting | Diabetes | 620 | 2026-02-07 |
| GZR4 NCT06767761 |
P3 | Active, not recruiting | Diabetes | 580 | 2026-03-19 |
| GZR33 Injection NCT07527078 |
P3 | Recruiting | Type 2 Diabetes (T2DM) | 350 | 2026-04-07 |
| GZR102 NCT07055386 |
P2 | Active, not recruiting | Type 2 Diabetes Mellitus (T2DM) | 90 | 2026-06-28 (+2 mo) |
| GZR4 NCT06767735 |
P3 | Active, not recruiting | Diabetes | 580 | 2026-08-01 (+6 mo) |
| GZR4 NCT07165223 |
P3 | Recruiting | Diabetes | 300 | 2026-11-10 |
| GZR101-80 NCT07387003 |
P2 | Not yet recruiting | Type 2 Diabetes (T2DM) | 345 | 2027-02-11 |
| GZR18 NCT07150975 |
P3 | Recruiting | Obesity/Overweight in Adult | 420 | 2027-06-30 |
| GZR18 injection NCT07493057 |
P3 | Recruiting | Obstructive Sleep Apnea (OSA) | 140 | 2027-11-14 |
| GZR18 injection NCT07501832 |
P3 | Recruiting | Obstructive Sleep Apnea (OSA) | 140 | 2028-09-28 |